Camcevi

Overview

leuprolide

GnRH agonist

• GnRH receptor agonist
• hyperglycemic effects
• lowers seizure threshold
• prolongs QT interval (known)
• pseudotumor cerebri

Contraindicated

• cisapride
Camcevi (leuprolide)

+

cisapride

1 interaction

Contraindicated

leuprolide + cisapride

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• domperidone
Camcevi (leuprolide)

+

domperidone

1 interaction

Contraindicated

leuprolide + domperidone

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. leuprolide efficacy (additive effects, androgen deprivation may prolong QT; domperidone may cause hyperprolactinemia, decr. GnRH receptors)

• dronedarone
Camcevi (leuprolide)

+

dronedarone

1 interaction

Contraindicated

leuprolide + dronedarone

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• levoketoconazole
Camcevi (leuprolide)

+

levoketoconazole

1 interaction

Contraindicated

leuprolide + levoketoconazole

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• pimozide
Camcevi (leuprolide)

+

pimozide

1 interaction

Contraindicated

leuprolide + pimozide

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• thioridazine
Camcevi (leuprolide)

+

thioridazine

1 interaction

Contraindicated

leuprolide + thioridazine

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. leuprolide efficacy (additive effects, androgen deprivation may prolong QT; thioridazine may cause hyperprolactinemia, decr. GnRH receptors)

Avoid/Use Alternative

• adagrasib
Camcevi (leuprolide)

+

adagrasib

1 interaction

Avoid/Use Alternative

leuprolide + adagrasib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• aldesleukin
Camcevi (leuprolide)

+

aldesleukin

1 interaction

Avoid/Use Alternative

leuprolide + aldesleukin

avoid combo: combo may incr. risk of seizures (additive effects)

• amifampridine
Camcevi (leuprolide)

+

amifampridine

1 interaction

Avoid/Use Alternative

leuprolide + amifampridine

consider alternative: combo may incr. risk of seizures (additive effects)

• amiodarone
Camcevi (leuprolide)

+

amiodarone

1 interaction

Avoid/Use Alternative

leuprolide + amiodarone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• anagrelide
Camcevi (leuprolide)

+

anagrelide

1 interaction

Avoid/Use Alternative

leuprolide + anagrelide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• apomorphine
Camcevi (leuprolide)

+

apomorphine

1 interaction

Avoid/Use Alternative

leuprolide + apomorphine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• arsenic trioxide
Camcevi (leuprolide)

+

arsenic trioxide

1 interaction

Avoid/Use Alternative

leuprolide + arsenic trioxide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• artemether/lumefantrine
Camcevi (leuprolide)

+

artemether/ lumefantrine

1 interaction

Avoid/Use Alternative

leuprolide + artemether/ lumefantrine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• asenapine
Camcevi (leuprolide)

+

asenapine

1 interaction

Avoid/Use Alternative

leuprolide + asenapine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. leuprolide efficacy (additive effects, androgen deprivation prolongs QT; antagonistic effects, asenapine may cause hyperprolactinemia, decr. GnRH receptors)

• azithromycin
Camcevi (leuprolide)

+

azithromycin

1 interaction

Avoid/Use Alternative

leuprolide + azithromycin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• bedaquiline
Camcevi (leuprolide)

+

bedaquiline

1 interaction

Avoid/Use Alternative

leuprolide + bedaquiline

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• cabozantinib
Camcevi (leuprolide)

+

cabozantinib

1 interaction

Avoid/Use Alternative

leuprolide + cabozantinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• ceritinib
Camcevi (leuprolide)

+

ceritinib

1 interaction

Avoid/Use Alternative

leuprolide + ceritinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• chloroquine
Camcevi (leuprolide)

+

chloroquine

1 interaction

Avoid/Use Alternative

leuprolide + chloroquine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• citalopram
Camcevi (leuprolide)

+

citalopram

1 interaction

Avoid/Use Alternative

leuprolide + citalopram

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects, androgen deprivation may prolong QT)

• clarithromycin
Camcevi (leuprolide)

+

clarithromycin

1 interaction

Avoid/Use Alternative

leuprolide + clarithromycin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• clofazimine
Camcevi (leuprolide)

+

clofazimine

1 interaction

Avoid/Use Alternative

leuprolide + clofazimine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• crizotinib
Camcevi (leuprolide)

+

crizotinib

1 interaction

Avoid/Use Alternative

leuprolide + crizotinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• desflurane
Camcevi (leuprolide)

+

desflurane

1 interaction

Avoid/Use Alternative

leuprolide + desflurane

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• desipramine
Camcevi (leuprolide)

+

desipramine

1 interaction

Avoid/Use Alternative

leuprolide + desipramine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• dexmedetomidine
Camcevi (leuprolide)

+

dexmedetomidine

1 interaction

Avoid/Use Alternative

leuprolide + dexmedetomidine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• dexmedetomidine injection
Camcevi (leuprolide)

+

dexmedetomidine injection

1 interaction

Avoid/Use Alternative

leuprolide + dexmedetomidine injection

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• disopyramide
Camcevi (leuprolide)

+

disopyramide

1 interaction

Avoid/Use Alternative

leuprolide + disopyramide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• dofetilide
Camcevi (leuprolide)

+

dofetilide

1 interaction

Avoid/Use Alternative

leuprolide + dofetilide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• donepezil
Camcevi (leuprolide)

+

donepezil

1 interaction

Avoid/Use Alternative

leuprolide + donepezil

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• dordaviprone
Camcevi (leuprolide)

+

dordaviprone

1 interaction

Avoid/Use Alternative

leuprolide + dordaviprone

use alternative or monitor ECG, electrolytes; separate admin.: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• droperidol
Camcevi (leuprolide)

+

droperidol

1 interaction

Avoid/Use Alternative

leuprolide + droperidol

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• efavirenz
Camcevi (leuprolide)

+

efavirenz

1 interaction

Avoid/Use Alternative

leuprolide + efavirenz

consider alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• encorafenib
Camcevi (leuprolide)

+

encorafenib

1 interaction

Avoid/Use Alternative

leuprolide + encorafenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• entrectinib
Camcevi (leuprolide)

+

entrectinib

1 interaction

Avoid/Use Alternative

leuprolide + entrectinib

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• ephedra
Camcevi (leuprolide)

+

ephedra

1 interaction

Avoid/Use Alternative

leuprolide + ephedra

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• epirubicin
Camcevi (leuprolide)

+

epirubicin

1 interaction

Avoid/Use Alternative

leuprolide + epirubicin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• eribulin
Camcevi (leuprolide)

+

eribulin

1 interaction

Avoid/Use Alternative

leuprolide + eribulin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• erythromycin
Camcevi (leuprolide)

+

erythromycin

1 interaction

Avoid/Use Alternative

leuprolide + erythromycin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• etrasimod
Camcevi (leuprolide)

+

etrasimod

1 interaction

Avoid/Use Alternative

leuprolide + etrasimod

consider alternative or monitor HR, ECG, electrolytes: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• fexinidazole
Camcevi (leuprolide)

+

fexinidazole

1 interaction

Avoid/Use Alternative

leuprolide + fexinidazole

if possible, do not initiate fexinidazole until 5 half-lives after leuprolide D/C; use alternative or monitor ECG, electrolytes during and x7 days after fexinidazole tx: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• flecainide
Camcevi (leuprolide)

+

flecainide

1 interaction

Avoid/Use Alternative

leuprolide + flecainide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• fluorouracil
Camcevi (leuprolide)

+

fluorouracil

1 interaction

Avoid/Use Alternative

leuprolide + fluorouracil

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• fluoxetine
Camcevi (leuprolide)

+

fluoxetine

1 interaction

Avoid/Use Alternative

leuprolide + fluoxetine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects, androgen deprivation may prolong QT)

• foscarnet
Camcevi (leuprolide)

+

foscarnet

1 interaction

Avoid/Use Alternative

leuprolide + foscarnet

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• gepotidacin
Camcevi (leuprolide)

+

gepotidacin

1 interaction

Avoid/Use Alternative

leuprolide + gepotidacin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• gilteritinib
Camcevi (leuprolide)

+

gilteritinib

1 interaction

Avoid/Use Alternative

leuprolide + gilteritinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• givinostat
Camcevi (leuprolide)

+

givinostat

1 interaction

Avoid/Use Alternative

leuprolide + givinostat

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• glasdegib
Camcevi (leuprolide)

+

glasdegib

1 interaction

Avoid/Use Alternative

leuprolide + glasdegib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• goserelin
Camcevi (leuprolide)

+

goserelin

1 interaction

Avoid/Use Alternative

leuprolide + goserelin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, intracranial HTN, papilledema, other adverse effects (additive effects, androgen deprivation may prolong QT; duplicate tx)

• grapefruit
Camcevi (leuprolide)

+

grapefruit

1 interaction

Avoid/Use Alternative

leuprolide + grapefruit

use alternative or monitor ECG, electrolytes w/ large amounts of grapefruit (>1L juice): combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• haloperidol
Camcevi (leuprolide)

+

haloperidol

1 interaction

Avoid/Use Alternative

leuprolide + haloperidol

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. leuprolide efficacy (additive effects, androgen deprivation may prolong QT; antagonistic effects, haloperidol may cause hyperprolactinemia which decr. number of GnRH receptors)

• hydroxychloroquine
Camcevi (leuprolide)

+

hydroxychloroquine

1 interaction

Avoid/Use Alternative

leuprolide + hydroxychloroquine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects, androgen deprivation may prolong QT)

• hydroxyzine
Camcevi (leuprolide)

+

hydroxyzine

1 interaction

Avoid/Use Alternative

leuprolide + hydroxyzine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• ibutilide
Camcevi (leuprolide)

+

ibutilide

1 interaction

Avoid/Use Alternative

leuprolide + ibutilide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• iloperidone
Camcevi (leuprolide)

+

iloperidone

1 interaction

Avoid/Use Alternative

leuprolide + iloperidone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. leuprolide efficacy (additive effects, androgen deprivation may prolong QT; iloperidone may cause hyperprolactinemia, decr. GnRH receptors)

• inotuzumab ozogamicin
Camcevi (leuprolide)

+

inotuzumab ozogamicin

1 interaction

Avoid/Use Alternative

leuprolide + inotuzumab ozogamicin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• iohexol
Camcevi (leuprolide)

+

iohexol

1 interaction

Avoid/Use Alternative

leuprolide + iohexol

avoid combo if intrathecal iohexol use: combo may incr. risk of seizures (additive effects)

• isoflurane
Camcevi (leuprolide)

+

isoflurane

1 interaction

Avoid/Use Alternative

leuprolide + isoflurane

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• ivabradine
Camcevi (leuprolide)

+

ivabradine

1 interaction

Avoid/Use Alternative

leuprolide + ivabradine

consider alternative or monitor HR, ECG, electrolytes: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• ivosidenib
Camcevi (leuprolide)

+

ivosidenib

1 interaction

Avoid/Use Alternative

leuprolide + ivosidenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• lefamulin
Camcevi (leuprolide)

+

lefamulin

1 interaction

Avoid/Use Alternative

leuprolide + lefamulin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• levofloxacin
Camcevi (leuprolide)

+

levofloxacin

1 interaction

Avoid/Use Alternative

leuprolide + levofloxacin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• lofexidine
Camcevi (leuprolide)

+

lofexidine

1 interaction

Avoid/Use Alternative

leuprolide + lofexidine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• lonafarnib
Camcevi (leuprolide)

+

lonafarnib

1 interaction

Avoid/Use Alternative

leuprolide + lonafarnib

use alternative or monitor HR, ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• loperamide
Camcevi (leuprolide)

+

loperamide

1 interaction

Avoid/Use Alternative

leuprolide + loperamide

use alternative or monitor ECG, electrolytes, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• lopinavir/ritonavir
Camcevi (leuprolide)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

leuprolide + lopinavir/ ritonavir

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• macimorelin
Camcevi (leuprolide)

+

macimorelin

1 interaction

Avoid/Use Alternative

leuprolide + macimorelin

avoid combo, allowing sufficient washout time before diagnostic test: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• methadone
Camcevi (leuprolide)

+

methadone

1 interaction

Avoid/Use Alternative

leuprolide + methadone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• mifepristone
Camcevi (leuprolide)

+

mifepristone

1 interaction

Avoid/Use Alternative

leuprolide + mifepristone

use alternative or monitor ECG, electrolytes if daily mifepristone use: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• mobocertinib
Camcevi (leuprolide)

+

mobocertinib

1 interaction

Avoid/Use Alternative

leuprolide + mobocertinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• moxifloxacin
Camcevi (leuprolide)

+

moxifloxacin

1 interaction

Avoid/Use Alternative

leuprolide + moxifloxacin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• nilotinib
Camcevi (leuprolide)

+

nilotinib

1 interaction

Avoid/Use Alternative

leuprolide + nilotinib

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• oliceridine
Camcevi (leuprolide)

+

oliceridine

1 interaction

Avoid/Use Alternative

leuprolide + oliceridine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• ondansetron
Camcevi (leuprolide)

+

ondansetron

1 interaction

Avoid/Use Alternative

leuprolide + ondansetron

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• osimertinib
Camcevi (leuprolide)

+

osimertinib

1 interaction

Avoid/Use Alternative

leuprolide + osimertinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• oxaliplatin
Camcevi (leuprolide)

+

oxaliplatin

1 interaction

Avoid/Use Alternative

leuprolide + oxaliplatin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• ozanimod
Camcevi (leuprolide)

+

ozanimod

1 interaction

Avoid/Use Alternative

leuprolide + ozanimod

consider alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• pacritinib
Camcevi (leuprolide)

+

pacritinib

1 interaction

Avoid/Use Alternative

leuprolide + pacritinib

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• paliperidone
Camcevi (leuprolide)

+

paliperidone

1 interaction

Avoid/Use Alternative

leuprolide + paliperidone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. leuprolide efficacy (additive effects, androgen deprivation may prolong QT; paliperidone may cause hyperprolactinemia, decr. GnRH receptors)

• palonosetron
Camcevi (leuprolide)

+

palonosetron

1 interaction

Avoid/Use Alternative

leuprolide + palonosetron

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• panobinostat
Camcevi (leuprolide)

+

panobinostat

1 interaction

Avoid/Use Alternative

leuprolide + panobinostat

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• pasireotide
Camcevi (leuprolide)

+

pasireotide

1 interaction

Avoid/Use Alternative

leuprolide + pasireotide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• pazopanib
Camcevi (leuprolide)

+

pazopanib

1 interaction

Avoid/Use Alternative

leuprolide + pazopanib

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• pentamidine
Camcevi (leuprolide)

+

pentamidine

1 interaction

Avoid/Use Alternative

leuprolide + pentamidine

use alternative or monitor ECG, electrolytes; risk may be lower w/ nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• phenobarbital
Camcevi (leuprolide)

+

phenobarbital

1 interaction

Avoid/Use Alternative

leuprolide + phenobarbital

avoid combo if neonatal seizure use; otherwise, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias; may alter seizure control (additive effects, androgen deprivation may prolong QT; antagonistic effects, leuprolide may decr. seizure threshold)

• pimavanserin
Camcevi (leuprolide)

+

pimavanserin

1 interaction

Avoid/Use Alternative

leuprolide + pimavanserin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• pitolisant
Camcevi (leuprolide)

+

pitolisant

1 interaction

Avoid/Use Alternative

leuprolide + pitolisant

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• ponesimod
Camcevi (leuprolide)

+

ponesimod

1 interaction

Avoid/Use Alternative

leuprolide + ponesimod

use alternative or monitor HR, ECG, electrolytes: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• procainamide
Camcevi (leuprolide)

+

procainamide

1 interaction

Avoid/Use Alternative

leuprolide + procainamide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• propafenone
Camcevi (leuprolide)

+

propafenone

1 interaction

Avoid/Use Alternative

leuprolide + propafenone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• quetiapine
Camcevi (leuprolide)

+

quetiapine

1 interaction

Avoid/Use Alternative

leuprolide + quetiapine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. leuprolide efficacy (additive effects, androgen deprivation may prolong QT; antagonistic effects, quetiapine may cause hyperprolactinemia which decr. number of GnRH receptors)

• quinidine (antiarrhythmic)
Camcevi (leuprolide)

+

quinidine (antiarrhythmic)

1 interaction

Avoid/Use Alternative

leuprolide + quinidine (antiarrhythmic)

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• quinidine (CYP2D6 inhibitor)
Camcevi (leuprolide)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Avoid/Use Alternative

leuprolide + quinidine (CYP2D6 inhibitor)

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• quinine
Camcevi (leuprolide)

+

quinine

1 interaction

Avoid/Use Alternative

leuprolide + quinine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• quizartinib
Camcevi (leuprolide)

+

quizartinib

1 interaction

Avoid/Use Alternative

leuprolide + quizartinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• revumenib
Camcevi (leuprolide)

+

revumenib

1 interaction

Avoid/Use Alternative

leuprolide + revumenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• ribociclib
Camcevi (leuprolide)

+

ribociclib

1 interaction

Avoid/Use Alternative

leuprolide + ribociclib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• rilpivirine
Camcevi (leuprolide)

+

rilpivirine

1 interaction

Avoid/Use Alternative

leuprolide + rilpivirine

consider alternative or monitor ECG, electrolytes; risk may be lower w/ IM rilpivirine: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• romidepsin
Camcevi (leuprolide)

+

romidepsin

1 interaction

Avoid/Use Alternative

leuprolide + romidepsin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• rucaparib
Camcevi (leuprolide)

+

rucaparib

1 interaction

Avoid/Use Alternative

leuprolide + rucaparib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• selpercatinib
Camcevi (leuprolide)

+

selpercatinib

1 interaction

Avoid/Use Alternative

leuprolide + selpercatinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• sertraline
Camcevi (leuprolide)

+

sertraline

1 interaction

Avoid/Use Alternative

leuprolide + sertraline

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects, androgen deprivation may prolong QT)

• sevoflurane
Camcevi (leuprolide)

+

sevoflurane

1 interaction

Avoid/Use Alternative

leuprolide + sevoflurane

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• siponimod
Camcevi (leuprolide)

+

siponimod

1 interaction

Avoid/Use Alternative

leuprolide + siponimod

consider alternative or monitor HR, ECG, electrolytes: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• solifenacin
Camcevi (leuprolide)

+

solifenacin

1 interaction

Avoid/Use Alternative

leuprolide + solifenacin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• sorafenib
Camcevi (leuprolide)

+

sorafenib

1 interaction

Avoid/Use Alternative

leuprolide + sorafenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• sotalol
Camcevi (leuprolide)

+

sotalol

1 interaction

Avoid/Use Alternative

leuprolide + sotalol

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• telavancin
Camcevi (leuprolide)

+

telavancin

1 interaction

Avoid/Use Alternative

leuprolide + telavancin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• tetrabenazine
Camcevi (leuprolide)

+

tetrabenazine

1 interaction

Avoid/Use Alternative

leuprolide + tetrabenazine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. leuprolide efficacy (additive effects, androgen deprivation may prolong QT; antagonistic effects, tetrabenazine may cause hyperprolactinemia which decr. number of GnRH receptors)

• toremifene
Camcevi (leuprolide)

+

toremifene

1 interaction

Avoid/Use Alternative

leuprolide + toremifene

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• tramadol
Camcevi (leuprolide)

+

tramadol

1 interaction

Avoid/Use Alternative

leuprolide + tramadol

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects, androgen deprivation may prolong QT)

• trazodone
Camcevi (leuprolide)

+

trazodone

1 interaction

Avoid/Use Alternative

leuprolide + trazodone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• tretinoin
Camcevi (leuprolide)

+

tretinoin

1 interaction

Avoid/Use Alternative

leuprolide + tretinoin

avoid combo: combo may incr. risk of intracranial HTN, papilledema (additive effects)

• triclabendazole
Camcevi (leuprolide)

+

triclabendazole

1 interaction

Avoid/Use Alternative

leuprolide + triclabendazole

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• trifluridine
Camcevi (leuprolide)

+

trifluridine

1 interaction

Avoid/Use Alternative

leuprolide + trifluridine

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• vandetanib
Camcevi (leuprolide)

+

vandetanib

1 interaction

Avoid/Use Alternative

leuprolide + vandetanib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• vemurafenib
Camcevi (leuprolide)

+

vemurafenib

1 interaction

Avoid/Use Alternative

leuprolide + vemurafenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• ziprasidone
Camcevi (leuprolide)

+

ziprasidone

1 interaction

Avoid/Use Alternative

leuprolide + ziprasidone

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. leuprolide efficacy (additive effects, androgen deprivation may prolong QT; ziprasidone may cause hyperprolactinemia, decr. GnRH receptors)

Monitor/Modify Tx

• acarbose
Camcevi (leuprolide)

+

acarbose

1 interaction

Monitor/Modify Tx

leuprolide + acarbose

monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• acitretin
Camcevi (leuprolide)

+

acitretin

1 interaction

Monitor/Modify Tx

leuprolide + acitretin

monitor pseudotumor cerebri s/sx: combo may incr. risk of intracranial HTN, papilledema (additive effects)

• albuterol
Camcevi (leuprolide)

+

albuterol

1 interaction

Monitor/Modify Tx

leuprolide + albuterol

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation prolongs QT)

• albuterol inhaled
Camcevi (leuprolide)

+

albuterol inhaled

1 interaction

Monitor/Modify Tx

leuprolide + albuterol inhaled

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation prolongs QT)

• alfuzosin
Camcevi (leuprolide)

+

alfuzosin

1 interaction

Monitor/Modify Tx

leuprolide + alfuzosin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• alogliptin
Camcevi (leuprolide)

+

alogliptin

1 interaction

Monitor/Modify Tx

leuprolide + alogliptin

monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• amisulpride
Camcevi (leuprolide)

+

amisulpride

1 interaction

Monitor/Modify Tx

leuprolide + amisulpride

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. leuprolide efficacy (additive effects, androgen deprivation may prolong QT; amisulpride may cause hyperprolactinemia which decr. number of GnRH receptors)

• amitriptyline
Camcevi (leuprolide)

+

amitriptyline

1 interaction

Monitor/Modify Tx

leuprolide + amitriptyline

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. leuprolide efficacy (additive effects, androgen deprivation may prolong QT; antagonistic effects, amitriptyline may cause hyperprolactinemia which decr. number of GnRH receptors)

• apalutamide
Camcevi (leuprolide)

+

apalutamide

1 interaction

Monitor/Modify Tx

leuprolide + apalutamide

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• arformoterol inhaled
Camcevi (leuprolide)

+

arformoterol inhaled

1 interaction

Monitor/Modify Tx

leuprolide + arformoterol inhaled

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation prolongs QT)

• asciminib
Camcevi (leuprolide)

+

asciminib

1 interaction

Monitor/Modify Tx

leuprolide + asciminib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• berotralstat
Camcevi (leuprolide)

+

berotralstat

1 interaction

Monitor/Modify Tx

leuprolide + berotralstat

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• bexagliflozin
Camcevi (leuprolide)

+

bexagliflozin

1 interaction

Monitor/Modify Tx

leuprolide + bexagliflozin

monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• bromocriptine
Camcevi (leuprolide)

+

bromocriptine

1 interaction

Monitor/Modify Tx

leuprolide + bromocriptine

monitor glucose in type 2 diabetes mellitus pts if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• buprenorphine
Camcevi (leuprolide)

+

buprenorphine

1 interaction

Monitor/Modify Tx

leuprolide + buprenorphine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• bupropion
Camcevi (leuprolide)

+

bupropion

1 interaction

Monitor/Modify Tx

leuprolide + bupropion

consider lower bupropion doses: combo may incr. risk of seizures (additive effects)

• canagliflozin
Camcevi (leuprolide)

+

canagliflozin

1 interaction

Monitor/Modify Tx

leuprolide + canagliflozin

monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• chlorpromazine
Camcevi (leuprolide)

+

chlorpromazine

1 interaction

Monitor/Modify Tx

leuprolide + chlorpromazine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. leuprolide efficacy (additive effects, androgen deprivation may prolong QT; antagonistic effects, phenothiazines may cause hyperprolactinemia which decr. number of GnRH receptors)

• ciprofloxacin
Camcevi (leuprolide)

+

ciprofloxacin

1 interaction

Monitor/Modify Tx

leuprolide + ciprofloxacin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• clomipramine
Camcevi (leuprolide)

+

clomipramine

1 interaction

Monitor/Modify Tx

leuprolide + clomipramine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures; combo may decr. leuprolide efficacy (additive effects, androgen deprivation may prolong QT)

• clozapine
Camcevi (leuprolide)

+

clozapine

1 interaction

Monitor/Modify Tx

leuprolide + clozapine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects, androgen deprivation may prolong QT)

• colesevelam
Camcevi (leuprolide)

+

colesevelam

1 interaction

Monitor/Modify Tx

leuprolide + colesevelam

monitor glucose in type 2 diabetes mellitus pts if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• cyclosporine
Camcevi (leuprolide)

+

cyclosporine

1 interaction

Monitor/Modify Tx

leuprolide + cyclosporine

monitor pseudotumor cerebri s/sx: combo may incr. risk of intracranial HTN, papilledema (additive effects)

• cysteamine
Camcevi (leuprolide)

+

cysteamine

1 interaction

Monitor/Modify Tx

leuprolide + cysteamine

monitor pseudotumor cerebri s/sx: combo may incr. risk of intracranial HTN, papilledema (additive effects)

• dapagliflozin
Camcevi (leuprolide)

+

dapagliflozin

1 interaction

Monitor/Modify Tx

leuprolide + dapagliflozin

monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• dasatinib
Camcevi (leuprolide)

+

dasatinib

1 interaction

Monitor/Modify Tx

leuprolide + dasatinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• demeclocycline
Camcevi (leuprolide)

+

demeclocycline

1 interaction

Monitor/Modify Tx

leuprolide + demeclocycline

monitor pseudotumor cerebri s/sx: combo may incr. risk of intracranial HTN, papilledema (additive effects)

• deutetrabenazine
Camcevi (leuprolide)

+

deutetrabenazine

1 interaction

Monitor/Modify Tx

leuprolide + deutetrabenazine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. leuprolide efficacy (additive effects, androgen deprivation may prolong QT; antagonistic effects, deutetrabenazine may cause hyperprolactinemia, decr. GnRH receptors)

• doxycycline
Camcevi (leuprolide)

+

doxycycline

1 interaction

Monitor/Modify Tx

leuprolide + doxycycline

monitor pseudotumor cerebri s/sx: combo may incr. risk of intracranial HTN, papilledema (additive effects)

• dulaglutide
Camcevi (leuprolide)

+

dulaglutide

1 interaction

Monitor/Modify Tx

leuprolide + dulaglutide

monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• eliglustat
Camcevi (leuprolide)

+

eliglustat

1 interaction

Monitor/Modify Tx

leuprolide + eliglustat

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• empagliflozin
Camcevi (leuprolide)

+

empagliflozin

1 interaction

Monitor/Modify Tx

leuprolide + empagliflozin

monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• eravacycline
Camcevi (leuprolide)

+

eravacycline

1 interaction

Monitor/Modify Tx

leuprolide + eravacycline

monitor pseudotumor cerebri s/sx: combo may incr. risk of intracranial HTN, papilledema (additive effects)

• ertugliflozin
Camcevi (leuprolide)

+

ertugliflozin

1 interaction

Monitor/Modify Tx

leuprolide + ertugliflozin

monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• escitalopram
Camcevi (leuprolide)

+

escitalopram

1 interaction

Monitor/Modify Tx

leuprolide + escitalopram

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures (additive effects, androgen deprivation may prolong QT)

• exenatide
Camcevi (leuprolide)

+

exenatide

1 interaction

Monitor/Modify Tx

leuprolide + exenatide

monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• fingolimod
Camcevi (leuprolide)

+

fingolimod

1 interaction

Monitor/Modify Tx

leuprolide + fingolimod

monitor electrolytes, ECG overnight during fingolimod initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• fluconazole
Camcevi (leuprolide)

+

fluconazole

1 interaction

Monitor/Modify Tx

leuprolide + fluconazole

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• formoterol inhaled
Camcevi (leuprolide)

+

formoterol inhaled

1 interaction

Monitor/Modify Tx

leuprolide + formoterol inhaled

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation prolongs QT)

• fostemsavir
Camcevi (leuprolide)

+

fostemsavir

1 interaction

Monitor/Modify Tx

leuprolide + fostemsavir

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• gemtuzumab ozogamicin
Camcevi (leuprolide)

+

gemtuzumab ozogamicin

1 interaction

Monitor/Modify Tx

leuprolide + gemtuzumab ozogamicin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• gepirone
Camcevi (leuprolide)

+

gepirone

1 interaction

Monitor/Modify Tx

leuprolide + gepirone

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• glimepiride
Camcevi (leuprolide)

+

glimepiride

1 interaction

Monitor/Modify Tx

leuprolide + glimepiride

monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• glipizide
Camcevi (leuprolide)

+

glipizide

1 interaction

Monitor/Modify Tx

leuprolide + glipizide

monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• glyburide
Camcevi (leuprolide)

+

glyburide

1 interaction

Monitor/Modify Tx

leuprolide + glyburide

monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• granisetron
Camcevi (leuprolide)

+

granisetron

1 interaction

Monitor/Modify Tx

leuprolide + granisetron

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• hydrocodone
Camcevi (leuprolide)

+

hydrocodone

1 interaction

Monitor/Modify Tx

leuprolide + hydrocodone

monitor ECG, electrolytes, especially if hydrocodone ER doses >160 mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• insulin
Camcevi (leuprolide)

+

insulin

1 interaction

Monitor/Modify Tx

leuprolide + insulin

monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• iopamidol
Camcevi (leuprolide)

+

iopamidol

1 interaction

Monitor/Modify Tx

leuprolide + iopamidol

caution advised if intrathecal iopamidol use; consider holding leuprolide at least 48h before and at least 24h after intrathecal iopamidol: combo may incr. risk of seizures (additive effects)

• lapatinib
Camcevi (leuprolide)

+

lapatinib

1 interaction

Monitor/Modify Tx

leuprolide + lapatinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• lenvatinib
Camcevi (leuprolide)

+

lenvatinib

1 interaction

Monitor/Modify Tx

leuprolide + lenvatinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• levalbuterol inhaled
Camcevi (leuprolide)

+

levalbuterol inhaled

1 interaction

Monitor/Modify Tx

leuprolide + levalbuterol inhaled

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• linagliptin
Camcevi (leuprolide)

+

linagliptin

1 interaction

Monitor/Modify Tx

leuprolide + linagliptin

monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• liraglutide
Camcevi (leuprolide)

+

liraglutide

1 interaction

Monitor/Modify Tx

leuprolide + liraglutide

monitor glucose in type 2 diabetes mellitus pts if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• lixisenatide
Camcevi (leuprolide)

+

lixisenatide

1 interaction

Monitor/Modify Tx

leuprolide + lixisenatide

monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• lumateperone
Camcevi (leuprolide)

+

lumateperone

1 interaction

Monitor/Modify Tx

leuprolide + lumateperone

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• lurasidone
Camcevi (leuprolide)

+

lurasidone

1 interaction

Monitor/Modify Tx

leuprolide + lurasidone

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. leuprolide efficacy (additive effects, androgen deprivation may prolong QT; lurasidone may cause hyperprolactinemia, decr. GnRH receptors)

• mavorixafor
Camcevi (leuprolide)

+

mavorixafor

1 interaction

Monitor/Modify Tx

leuprolide + mavorixafor

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• mefloquine
Camcevi (leuprolide)

+

mefloquine

1 interaction

Monitor/Modify Tx

leuprolide + mefloquine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• meperidine
Camcevi (leuprolide)

+

meperidine

1 interaction

Monitor/Modify Tx

leuprolide + meperidine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• metformin
Camcevi (leuprolide)

+

metformin

1 interaction

Monitor/Modify Tx

leuprolide + metformin

monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• metronidazole
Camcevi (leuprolide)

+

metronidazole

1 interaction

Monitor/Modify Tx

leuprolide + metronidazole

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• midostaurin
Camcevi (leuprolide)

+

midostaurin

1 interaction

Monitor/Modify Tx

leuprolide + midostaurin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• miglitol
Camcevi (leuprolide)

+

miglitol

1 interaction

Monitor/Modify Tx

leuprolide + miglitol

monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• minocycline
Camcevi (leuprolide)

+

minocycline

1 interaction

Monitor/Modify Tx

leuprolide + minocycline

monitor pseudotumor cerebri s/sx: combo may incr. risk of intracranial HTN, papilledema (additive effects)

• mirtazapine
Camcevi (leuprolide)

+

mirtazapine

1 interaction

Monitor/Modify Tx

leuprolide + mirtazapine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• nateglinide
Camcevi (leuprolide)

+

nateglinide

1 interaction

Monitor/Modify Tx

leuprolide + nateglinide

monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• ofloxacin
Camcevi (leuprolide)

+

ofloxacin

1 interaction

Monitor/Modify Tx

leuprolide + ofloxacin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• olodaterol inhaled
Camcevi (leuprolide)

+

olodaterol inhaled

1 interaction

Monitor/Modify Tx

leuprolide + olodaterol inhaled

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• omadacycline
Camcevi (leuprolide)

+

omadacycline

1 interaction

Monitor/Modify Tx

leuprolide + omadacycline

monitor pseudotumor cerebri s/sx: combo may incr. risk of intracranial HTN, papilledema (additive effects)

• osilodrostat
Camcevi (leuprolide)

+

osilodrostat

1 interaction

Monitor/Modify Tx

leuprolide + osilodrostat

monitor ECG, electrolytes: combo may incr. risk of QT interval prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• palovarotene
Camcevi (leuprolide)

+

palovarotene

1 interaction

Monitor/Modify Tx

leuprolide + palovarotene

monitor pseudotumor cerebri s/sx: combo may incr. risk of intracranial HTN, papilledema (additive effects)

• pioglitazone
Camcevi (leuprolide)

+

pioglitazone

1 interaction

Monitor/Modify Tx

leuprolide + pioglitazone

monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• posaconazole
Camcevi (leuprolide)

+

posaconazole

1 interaction

Monitor/Modify Tx

leuprolide + posaconazole

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• pralsetinib
Camcevi (leuprolide)

+

pralsetinib

1 interaction

Monitor/Modify Tx

leuprolide + pralsetinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• pramlintide
Camcevi (leuprolide)

+

pramlintide

1 interaction

Monitor/Modify Tx

leuprolide + pramlintide

monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• primaquine
Camcevi (leuprolide)

+

primaquine

1 interaction

Monitor/Modify Tx

leuprolide + primaquine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• promethazine
Camcevi (leuprolide)

+

promethazine

1 interaction

Monitor/Modify Tx

leuprolide + promethazine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, seizures; may decr. leuprolide efficacy (additive effects, androgen deprivation may prolong QT; antagonistic effects, phenothiazines may cause hyperprolactinemia which decr. number of GnRH receptors)

• ranolazine
Camcevi (leuprolide)

+

ranolazine

1 interaction

Monitor/Modify Tx

leuprolide + ranolazine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• relugolix
Camcevi (leuprolide)

+

relugolix

1 interaction

Monitor/Modify Tx

leuprolide + relugolix

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• repaglinide
Camcevi (leuprolide)

+

repaglinide

1 interaction

Monitor/Modify Tx

leuprolide + repaglinide

monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• rosiglitazone
Camcevi (leuprolide)

+

rosiglitazone

1 interaction

Monitor/Modify Tx

leuprolide + rosiglitazone

monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• sacituzumab govitecan
Camcevi (leuprolide)

+

sacituzumab govitecan

1 interaction

Monitor/Modify Tx

leuprolide + sacituzumab govitecan

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• salmeterol inhaled
Camcevi (leuprolide)

+

salmeterol inhaled

1 interaction

Monitor/Modify Tx

leuprolide + salmeterol inhaled

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• sarecycline
Camcevi (leuprolide)

+

sarecycline

1 interaction

Monitor/Modify Tx

leuprolide + sarecycline

monitor pseudotumor cerebri s/sx: combo may incr. risk of intracranial HTN, papilledema (additive effects)

• saxagliptin
Camcevi (leuprolide)

+

saxagliptin

1 interaction

Monitor/Modify Tx

leuprolide + saxagliptin

monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• sebetralstat
Camcevi (leuprolide)

+

sebetralstat

1 interaction

Monitor/Modify Tx

leuprolide + sebetralstat

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• semaglutide
Camcevi (leuprolide)

+

semaglutide

1 interaction

Monitor/Modify Tx

leuprolide + semaglutide

if prostate cancer use in type 2 diabetes mellitus pts, monitor glucose: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• sitagliptin
Camcevi (leuprolide)

+

sitagliptin

1 interaction

Monitor/Modify Tx

leuprolide + sitagliptin

monitor glucose if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• somatropin
Camcevi (leuprolide)

+

somatropin

1 interaction

Monitor/Modify Tx

leuprolide + somatropin

monitor pseudotumor cerebri s/sx: combo may incr. risk of intracranial HTN, papilledema (additive effects)

• sunitinib
Camcevi (leuprolide)

+

sunitinib

1 interaction

Monitor/Modify Tx

leuprolide + sunitinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• tacrolimus
Camcevi (leuprolide)

+

tacrolimus

1 interaction

Monitor/Modify Tx

leuprolide + tacrolimus

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• tazemetostat
Camcevi (leuprolide)

+

tazemetostat

1 interaction

Monitor/Modify Tx

leuprolide + tazemetostat

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• terbutaline
Camcevi (leuprolide)

+

terbutaline

1 interaction

Monitor/Modify Tx

leuprolide + terbutaline

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• tetracycline
Camcevi (leuprolide)

+

tetracycline

1 interaction

Monitor/Modify Tx

leuprolide + tetracycline

monitor pseudotumor cerebri s/sx: combo may incr. risk of intracranial HTN, papilledema (additive effects)

• tigecycline
Camcevi (leuprolide)

+

tigecycline

1 interaction

Monitor/Modify Tx

leuprolide + tigecycline

monitor pseudotumor cerebri s/sx: combo may incr. risk of intracranial HTN, papilledema (additive effects)

• tirzepatide
Camcevi (leuprolide)

+

tirzepatide

1 interaction

Monitor/Modify Tx

leuprolide + tirzepatide

monitor glucose in type 2 diabetes mellitus pts if prostate cancer use: combo may decr. antidiabetic agent efficacy (antagonistic effects)

• tolterodine
Camcevi (leuprolide)

+

tolterodine

1 interaction

Monitor/Modify Tx

leuprolide + tolterodine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• valbenazine
Camcevi (leuprolide)

+

valbenazine

1 interaction

Monitor/Modify Tx

leuprolide + valbenazine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• vardenafil
Camcevi (leuprolide)

+

vardenafil

1 interaction

Monitor/Modify Tx

leuprolide + vardenafil

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• venlafaxine
Camcevi (leuprolide)

+

venlafaxine

1 interaction

Monitor/Modify Tx

leuprolide + venlafaxine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• vilanterol inhaled
Camcevi (leuprolide)

+

vilanterol inhaled

1 interaction

Monitor/Modify Tx

leuprolide + vilanterol inhaled

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• voclosporin
Camcevi (leuprolide)

+

voclosporin

1 interaction

Monitor/Modify Tx

leuprolide + voclosporin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• voriconazole
Camcevi (leuprolide)

+

voriconazole

1 interaction

Monitor/Modify Tx

leuprolide + voriconazole

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

Caution Advised

• acetazolamide
Camcevi (leuprolide)

+

acetazolamide

1 interaction

Caution Advised

leuprolide + acetazolamide

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• brivaracetam
Camcevi (leuprolide)

+

brivaracetam

1 interaction

Caution Advised

leuprolide + brivaracetam

caution advised: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• busulfan
Camcevi (leuprolide)

+

busulfan

1 interaction

Caution Advised

leuprolide + busulfan

caution advised: combo may incr. risk of seizures (additive effects)

• cannabidiol
Camcevi (leuprolide)

+

cannabidiol

1 interaction

Caution Advised

leuprolide + cannabidiol

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• carbamazepine
Camcevi (leuprolide)

+

carbamazepine

1 interaction

Caution Advised

leuprolide + carbamazepine

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• cenobamate
Camcevi (leuprolide)

+

cenobamate

1 interaction

Caution Advised

leuprolide + cenobamate

caution advised: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• chlorambucil
Camcevi (leuprolide)

+

chlorambucil

1 interaction

Caution Advised

leuprolide + chlorambucil

caution advised: combo may incr. risk of seizures (additive effects)

• clobazam
Camcevi (leuprolide)

+

clobazam

1 interaction

Caution Advised

leuprolide + clobazam

caution advised: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• clonazepam
Camcevi (leuprolide)

+

clonazepam

1 interaction

Caution Advised

leuprolide + clonazepam

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• clorazepate
Camcevi (leuprolide)

+

clorazepate

1 interaction

Caution Advised

leuprolide + clorazepate

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• diazepam
Camcevi (leuprolide)

+

diazepam

1 interaction

Caution Advised

leuprolide + diazepam

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• eslicarbazepine acetate
Camcevi (leuprolide)

+

eslicarbazepine acetate

1 interaction

Caution Advised

leuprolide + eslicarbazepine acetate

caution advised: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• ethosuximide
Camcevi (leuprolide)

+

ethosuximide

1 interaction

Caution Advised

leuprolide + ethosuximide

caution advised: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• felbamate
Camcevi (leuprolide)

+

felbamate

1 interaction

Caution Advised

leuprolide + felbamate

caution advised: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• fenfluramine
Camcevi (leuprolide)

+

fenfluramine

1 interaction

Caution Advised

leuprolide + fenfluramine

caution advised: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• fluphenazine
Camcevi (leuprolide)

+

fluphenazine

1 interaction

Caution Advised

leuprolide + fluphenazine

caution advised: combo may decr. leuprolide efficacy (fluphenazine may cause hyperprolactinemia, decr. GnRH receptors)

• fluvoxamine
Camcevi (leuprolide)

+

fluvoxamine

1 interaction

Caution Advised

leuprolide + fluvoxamine

caution advised: combo may incr. risk of seizures (additive effects)

• fosphenytoin
Camcevi (leuprolide)

+

fosphenytoin

1 interaction

Caution Advised

leuprolide + fosphenytoin

caution advised: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• gabapentin
Camcevi (leuprolide)

+

gabapentin

1 interaction

Caution Advised

leuprolide + gabapentin

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• ganaxolone
Camcevi (leuprolide)

+

ganaxolone

1 interaction

Caution Advised

leuprolide + ganaxolone

caution advised: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• lacosamide
Camcevi (leuprolide)

+

lacosamide

1 interaction

Caution Advised

leuprolide + lacosamide

caution advised: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• lamotrigine
Camcevi (leuprolide)

+

lamotrigine

1 interaction

Caution Advised

leuprolide + lamotrigine

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• levetiracetam
Camcevi (leuprolide)

+

levetiracetam

1 interaction

Caution Advised

leuprolide + levetiracetam

caution advised: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• lorazepam
Camcevi (leuprolide)

+

lorazepam

1 interaction

Caution Advised

leuprolide + lorazepam

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• loxapine
Camcevi (leuprolide)

+

loxapine

1 interaction

Caution Advised

leuprolide + loxapine

caution advised: combo may decr. GnRH agonist efficacy (loxapine may cause hyperprolactinemia which decr. number of GnRH receptors)

• magnesium citrate
Camcevi (leuprolide)

+

magnesium citrate

1 interaction

Caution Advised

leuprolide + magnesium citrate

caution advised, especially if magnesium citrate bowel prep use: combo may incr. risk of seizures (additive effects)

• methsuximide
Camcevi (leuprolide)

+

methsuximide

1 interaction

Caution Advised

leuprolide + methsuximide

caution advised: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• metoclopramide
Camcevi (leuprolide)

+

metoclopramide

1 interaction

Caution Advised

leuprolide + metoclopramide

caution advised: combo may decr. leuprolide efficacy (metoclopramide may cause hyperprolactinemia which decr. number of GnRH receptors)

• midazolam
Camcevi (leuprolide)

+

midazolam

1 interaction

Caution Advised

leuprolide + midazolam

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• molindone
Camcevi (leuprolide)

+

molindone

1 interaction

Caution Advised

leuprolide + molindone

caution advised: combo may decr. leuprolide efficacy (molindone may cause hyperprolactinemia, decr. GnRH receptors)

• olanzapine
Camcevi (leuprolide)

+

olanzapine

1 interaction

Caution Advised

leuprolide + olanzapine

caution advised: combo may decr. leuprolide efficacy (olanzapine may cause hyperprolactinemia which decr. number of GnRH receptors)

• oxcarbazepine
Camcevi (leuprolide)

+

oxcarbazepine

1 interaction

Caution Advised

leuprolide + oxcarbazepine

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• paroxetine
Camcevi (leuprolide)

+

paroxetine

1 interaction

Caution Advised

leuprolide + paroxetine

caution advised: combo may incr. risk of seizures (additive effects)

• perampanel
Camcevi (leuprolide)

+

perampanel

1 interaction

Caution Advised

leuprolide + perampanel

caution advised: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• perphenazine
Camcevi (leuprolide)

+

perphenazine

1 interaction

Caution Advised

leuprolide + perphenazine

caution advised: combo may decr. leuprolide efficacy (phenothiazines may cause hyperprolactinemia which decr. number of GnRH receptors)

• phenytoin
Camcevi (leuprolide)

+

phenytoin

1 interaction

Caution Advised

leuprolide + phenytoin

caution advised: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• polyethylene glycol
Camcevi (leuprolide)

+

polyethylene glycol

1 interaction

Caution Advised

leuprolide + polyethylene glycol

caution advised, especially if polyethylene glycol bowel prep use: combo may incr. risk of seizures (additive effects)

• polyethylene glycol/electrolytes
Camcevi (leuprolide)

+

polyethylene glycol/ electrolytes

1 interaction

Caution Advised

leuprolide + polyethylene glycol/ electrolytes

caution advised: combo may incr. risk of seizures (additive effects)

• pregabalin
Camcevi (leuprolide)

+

pregabalin

1 interaction

Caution Advised

leuprolide + pregabalin

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• primidone
Camcevi (leuprolide)

+

primidone

1 interaction

Caution Advised

leuprolide + primidone

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• prochlorperazine
Camcevi (leuprolide)

+

prochlorperazine

1 interaction

Caution Advised

leuprolide + prochlorperazine

caution advised: combo may decr. leuprolide efficacy (phenothiazines may cause hyperprolactinemia which decr. number of GnRH receptors)

• risperidone
Camcevi (leuprolide)

+

risperidone

1 interaction

Caution Advised

leuprolide + risperidone

caution advised: combo may decr. leuprolide efficacy (risperidone may cause hyperprolactinemia, decr. GnRH receptors)

• rufinamide
Camcevi (leuprolide)

+

rufinamide

1 interaction

Caution Advised

leuprolide + rufinamide

caution advised: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• sodium picosulfate
Camcevi (leuprolide)

+

sodium picosulfate

1 interaction

Caution Advised

leuprolide + sodium picosulfate

caution advised: combo may incr. risk of seizures (additive effects)

• stiripentol
Camcevi (leuprolide)

+

stiripentol

1 interaction

Caution Advised

leuprolide + stiripentol

caution advised: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• sulfate bowel prep
Camcevi (leuprolide)

+

sulfate bowel prep

1 interaction

Caution Advised

leuprolide + sulfate bowel prep

caution advised: combo may incr. risk of seizures (additive effects)

• thiothixene
Camcevi (leuprolide)

+

thiothixene

1 interaction

Caution Advised

leuprolide + thiothixene

caution advised: combo may decr. GnRH agonist efficacy (thiothixene may cause hyperprolactinemia which decr. number of GnRH receptors)

• tiagabine
Camcevi (leuprolide)

+

tiagabine

1 interaction

Caution Advised

leuprolide + tiagabine

caution advised: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• topiramate
Camcevi (leuprolide)

+

topiramate

1 interaction

Caution Advised

leuprolide + topiramate

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• treosulfan
Camcevi (leuprolide)

+

treosulfan

1 interaction

Caution Advised

leuprolide + treosulfan

caution advised: combo may incr. risk of seizures (additive effects)

• trifluoperazine
Camcevi (leuprolide)

+

trifluoperazine

1 interaction

Caution Advised

leuprolide + trifluoperazine

caution advised: combo may decr. leuprolide efficacy (phenothiazines may cause hyperprolactinemia which decr. number of GnRH receptors)

• valproic acid
Camcevi (leuprolide)

+

valproic acid

1 interaction

Caution Advised

leuprolide + valproic acid

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• verapamil
Camcevi (leuprolide)

+

verapamil

1 interaction

Caution Advised

leuprolide + verapamil

caution advised: combo may decr. leuprolide efficacy (verapamil may cause hyperprolactinemia which decr. number of GnRH receptors)

• vigabatrin
Camcevi (leuprolide)

+

vigabatrin

1 interaction

Caution Advised

leuprolide + vigabatrin

caution advised: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)

• zonisamide
Camcevi (leuprolide)

+

zonisamide

1 interaction

Caution Advised

leuprolide + zonisamide

caution advised: combo may alter seizure control (antagonistic effects, leuprolide may decr. seizure threshold)